Search form

Latest News

Quidel Completes Acquisition of InflammaDry(R) and AdenoPlus(R) Eye-Health Businesses

SAN DIEGO, CA -- (Marketwired) -- --
Quidel Corporation
(NASDAQ: QDEL), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced today it completed the acquisition of the InflammaDry® and AdenoPlus® diagnostic businesses from RPS Diagnostics, a developer and manufacturer of rapid, point-of-care (POC) diagnostic tests for the eye health and primary care markets, for approximately $14 million in cash.

Read More »


Are you a determined, optimistic, team player? Quidel is looking for talented innovators who want to be part of revolutionizing medical diagnostics.

View Current Job Openings


We appreciate your efforts to improve patient care, physician services, and laboratory efficiency. We know that you will appreciate the value that Quidel brings in delivering diagnostics that do not sacrifice accuracy or ease-of-use. Please explore this site for helpful resources and how you can contact us for further support.